Phio Pharmaceuticals (NASDAQ:PHIO) Stock Price Down 5.8% – Here’s What Happened

Phio Pharmaceuticals Corp. (NASDAQ:PHIO)’s stock price was down 5.8% on Monday . The company traded as low as $1.78 and last traded at $1.78. Approximately 419,772 shares were traded during trading, a decline of 97% from the average daily volume of 14,347,903 shares. The stock had previously closed at $1.89.

Phio Pharmaceuticals Trading Down 5.8 %

The company has a market capitalization of $12.26 million, a P/E ratio of -0.16 and a beta of 1.53. The firm’s 50 day moving average price is $2.40 and its two-hundred day moving average price is $2.76.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.